Quanterix, Alzheimer’s Drug Discovery Foundation partner to accelerate AD detection test

Quanterix Corp. announced it has partnered with the Alzheimer’s Drug Discovery Foundation to accelerate the development of a multi-analyte plasma test for early detection of Alzheimer’s disease.

Through the partnership, the Alzheimer’s Drug Discovery Foundation (ADDF) will fund a series of clinical trials to validate the test in collaboration with Amsterdam University Medical Centers.

“We are in a historic moment with plasma-based biomarkers for Alzheimer’s disease detection nearing clinical implementation,” Charlotte E. Teunissen, PhD, professor at Amsterdam UMC who will lead the trials for ADDF, said in a released statement from the foundation. “This partnership and funding with the ADDF will help further drive the rapid progress in this area just in time for the arrival of new therapeutics. We will be looking to validate the Simoa multi-analyte test for use in both memory care and primary care settings, in persons with worries about their cognition.”

The research will be coordinated through Quanterix’s Simoa Accelerator Services Lab, which supports the research of more than 400 companies and accelerates drug approval timelines through the detection of biomarkers at the lowest possible levels.

“We have long believed the path to approved Alzheimer's treatments starts with a better way to diagnose patients and monitor their response to therapy,” Howard Fillit, MD, co-founder and chief medical officer of ADDF, said in the release. “Through the diagnostics accelerator, the ADDF is accelerating the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias, which are essential to driving research forward, allowing us to enroll the right patients in clinical trials and track their progress.”